The 21st CPHI and the 16th PMEC China were successfully held from June 19th to 21st, 2023, at the SNIECe Shanghai New International Expo Center. JEWIM PHARMA, a leading inhalation pharmaceutical company in China, participated in the exhibition.
    During the event, JEWIM PHARMA welcomed over 500 clients from more than 100 countries, including regulatory markets such as the United States, Germany, the United Kingdom, France, Australia, and Japan, as well as emerging markets in CIS, GCC, Southeast Asia, Latin America, and Africa. The company established clear cooperation intentions with the majority of clients, receiving praise for its professional approach, visually appealing booth, and attentive service.
    The Risen-Sun API marketing team, which also exhibited at the event, held initial face-to-face communications with partners, introducing JEWIM PHARMA's API division and paving the way for the international promotion of Risen-Sun products.
The International Business Division and Formulation Research Institute collaborated closely, implementing innovative business models and establishing a global marketing approach. Multiple commercial relationships were built, including CDMO for intermediate raw materials, technology transfers, License In/Out, and CSO, solidifying strong collaborations. The Production and Supply Chain departments gathered valuable information, supporting the company's internationalization strategy and implementing the concept of "all-staff marketing."
    The successful three-day exhibition reinforces JEWIM PHARMA's commitment to responsibility, innovation, and excellence. With a customer-centric approach and a focus on long-term relationships, the company aims to create new value for human health and provide stable, high-quality services to clients, fostering mutual development.
In October this year, the Overseas Business Division will represent the company at the CPHI exhibition in Barcelona, Spain, further promoting     JEWIM PHARMA's reliable products and services to global customers.